12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Growth hormone is permissive for neoplastic colon growth

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Significance

          Growth hormone (GH) excess in acromegaly is associated with increased colon polyps and cancer, whereas short-stature humans harboring a GH receptor mutation do not develop cancer. Administration of a GH receptor blocker in acromegaly patients induced colon p53. In contrast, p53 is suppressed by GH in colon cells, in vivo in colon tissue, and in induced pluripotent stem cell-derived intestinal organoids. GH excess leads to cell survival with downregulated adenomatous polyposis coli, nuclear β-catenin accumulation, and increased epithelial–mesenchymal transition factors. Because locally expressed GH is abundant in conditions predisposing to colon cancer, GH appears to be a molecular component of the milieu permissive for neoplastic colon growth. These results explain the protective effects of GH deficiency against development of neoplasms.

          Abstract

          Growth hormone (GH) excess in acromegaly is associated with increased precancerous colon polyps and soft tissue adenomas, whereas short-stature humans harboring an inactivating GH receptor mutation do not develop cancer. We show that locally expressed colon GH is abundant in conditions predisposing to colon cancer and in colon adenocarcinoma-associated stromal fibroblasts. Administration of a GH receptor (GHR) blocker in acromegaly patients induced colon p53 and adenomatous polyposis coli (APC), reversing progrowth GH signals. p53 was also induced in skin fibroblasts derived from short-statured humans with mutant GHR. GH-deficient prophet of pituitary-specific positive transcription factor 1 ( Prop1) −/− mice exhibited induced colon p53 levels, and cross-breeding them with Apc min+/− mice that normally develop intestinal and colon tumors resulted in GH-deficient double mutants with markedly decreased tumor number and size. We also demonstrate that GH suppresses p53 and reduces apoptosis in human colon cell lines as well as in induced human pluripotent stem cell-derived intestinal organoids, and confirm in vivo that GH suppresses colon mucosal p53/p21. GH excess leads to decreased colon cell phosphatase and tensin homolog deleted on chromosome 10 (PTEN), increased cell survival with down-regulated APC, nuclear β-catenin accumulation, and increased epithelial–mesenchymal transition factors and colon cell motility. We propose that GH is a molecular component of the “field change” milieu permissive for neoplastic colon growth.

          Related collections

          Author and article information

          Journal
          Proc Natl Acad Sci U S A
          Proc. Natl. Acad. Sci. U.S.A
          pnas
          pnas
          PNAS
          Proceedings of the National Academy of Sciences of the United States of America
          National Academy of Sciences
          0027-8424
          1091-6490
          7 June 2016
          25 May 2016
          : 113
          : 23
          : E3250-E3259
          Affiliations
          [1] aPituitary Center, Department of Medicine, Cedars-Sinai Medical Center , Los Angeles, CA 90048;
          [2] bDepartment of Medicine, Board of Governors Regenerative Medicine Institute, Cedars-Sinai Medical Center , Los Angeles, CA 90048;
          [3] cDepartment of Medicine, F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Cedars-Sinai Medical Center , Los Angeles, CA 90048
          Author notes
          1To whom correspondence should be addressed. Email: melmed@ 123456csmc.edu .

          Edited by David W. Russell, University of Texas Southwestern Medical Center, Dallas, TX, and approved May 2, 2016 (received for review January 12, 2016)

          Author contributions: V.C., C.Z., A.B.-S., M.U., and S.M. designed research; V.C., S.Z., C.Z., M.V.R., T.A., R.B., M.W., K.W., and V.A.L. performed research; V.C., S.Z., C.Z., M.V.R., A.B.-S., M.U., and S.M. analyzed data; and V.C. and S.M. wrote the paper.

          Article
          PMC4988562 PMC4988562 4988562 201600561
          10.1073/pnas.1600561113
          4988562
          27226307
          8717c065-6921-43a6-8e57-570393c06b99
          History
          Page count
          Pages: 10
          Funding
          Funded by: HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 100000062
          Award ID: DK103198; DK007770
          Categories
          PNAS Plus
          Biological Sciences
          Medical Sciences
          PNAS Plus

          acromegaly,growth hormone,colon,growth hormone deficiency

          Comments

          Comment on this article